Navigation Links
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
Date:3/6/2009

CORONA, Calif., March 6 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has reached a settlement with Elan Corporation, Plc on outstanding patent litigation related to Watson's generic version of Naprelan(R) (naproxen sodium) tablets.

Under the terms of the agreement, Watson will pay Elan $18 million in full settlement of all disputes related to Watson's development, manufacturing, marketing and sale of its naproxen sodium product. Watson also has agreed not to market or sell its naproxen sodium product until the expiration or final finding of invalidity or unenforceability of U.S. Patent No. 5,637,320. Other details concerning the settlement have not been disclosed.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes generic and specialty brand pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceutical's Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Naprelan(R) is a registered trademark of Elan Corporation, Plc

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
2. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
3. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
4. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
5. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
6. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
7. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
8. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event
9. Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
10. Watson Enters Into Agreement to Acquire Products Related to Tevas Proposed Acquisition of Barr
11. Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... Plains, NY (PRWEB) , ... April 22, 2017 ... ... Report, which shows that U.S. consumers can save an average of 70% when ... greater savings (up to 97%) are available when purchasing from other countries. The ...
(Date:4/22/2017)... ... ... San Juan Capistrano summer camp team at the Boys and Girls Club of South ... provide physical activities for all campers. To read the report, click here or ... in specialty camps that focus on what the report terms as “sitting subjects” like coding ...
(Date:4/21/2017)... ... , ... Providing broad access to life-saving drugs and rewarding the innovators who ... to address this problem. , That was the message from Dana Goldman, PhD, Leonard ... University of Southern California, who served as the keynote speaker for Western University of ...
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... ... April 21, 2017 , ... Evoke Therapy Programs , ... kicked off its 4th annual Forum for Innovative Treatment Solutions (FITS), which runs ... Therapy for Mental Health and Addiction.” , FITS’ 2017 keynote presenters will ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... April 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... biopharmaceutical company developing new treatments for cancer and ... of its previously announced underwritten public offering of ... public offering price of $2.00 per share, before ... expenses payable by Sorrento.  The net proceeds to ...
(Date:4/18/2017)... , April 18, 2017  Cardinal Health (NYSE: ... 1 fiscal 2017 earnings per share (EPS) guidance ... 2019.  This is in conjunction with this morning,s announcement ... Vein Thrombosis and Nutritional Insufficiency businesses. Cardinal ... continuing operations will be at the bottom of its ...
Breaking Medicine Technology: